Simcere Pharma has partnered with Bristol-Myers Squibb to co-develop a cancer molecule. In return for exclusive China rights to BMS-817378, a small molecule MET/VEGFR-2 inhibitor, Simcere will conduct a first-in-human clinical trial of the drug candidate as a first step toward SFDA approval. Financial details of the partnership were not disclosed. More details....

Stock Symbols: (NYSE: SCR) (NYSE: BMY)